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ABSTRACT: The X-ray structure of benzoylformate decar-
boxylase (BFDC) from Pseudomonas putida ATCC 12633
shows it to be a tetramer. This was believed to be typical of all
thiamin diphosphate-dependent decarboxylases until recently
when the structure of KdcA, a branched-chain 2-keto acid decarboxylase from Lactococcus lactis, showed it to be a homodimer.
This lent credence to earlier unfolding experiments on pyruvate decarboxylase from Saccharomyces cerevisiae that indicated that it
might be active as a dimer. To investigate this possibility in BFDC, we sought to shift the equilibrium toward dimer formation.
Point mutations were made in the noncatalytic monomer−monomer interfaces, but these had a minimal eﬀect on both tetramer
formation and catalytic activity. Subsequently, the R141E/Y288A/A306F variant was shown by analytical ultracentrifugation to
be partially dimeric. It was also found to be catalytically inactive. Further experiments revealed that just two mutations, R141E
and A306F, were suﬃcient to markedly alter the dimer−tetramer equilibrium and to provide an ∼450-fold decrease in kcat.
Equilibrium denaturation studies suggested that the residual activity was possibly due to the presence of residual tetramer. The
structures of the R141E and A306F variants, determined to <1.5 Å resolution, hinted that disruption of the monomer interfaces
will be accompanied by movement of a loop containing Leu109 and Leu110. As these residues contribute to the hydrophobicity
of the active site and the correct positioning of the substrate, it seems that tetramer formation may well be critical to the catalytic
activity of BFDC.
Oligomerization of proteins in biological systems is acommon phenomenon, and protein−protein interactions
are often involved in critical cellular processes. The destabiliza-
tion of interfaces in multimeric protein complexes is thought to
contribute to diseases ranging from neurodegenerative disorders
to muscular dystrophy.1−3 Because proteins rarely act alone in
vivo, predicting networks of protein−protein interactions, i.e., the
“interactome”, has become fundamental to the development of
systems biology.4−6 As a consequence, predicting how any given
protein will interact with other biomolecules, understanding the
forces stabilizing protein−protein interfaces, and learning how to
destabilize an individual interface have become the focus of much
research.7−9
One of the most common protein−protein interactions is self-
association.10,11 In essence, this allows a single gene of relatively
short length to encode a large protein system by allowing
multiple peptide sequences encoded from that gene to interact
and form a large multimeric protein. In addition to a reduced
genome and fewer problems with transcription, this system
provides beneﬁts such as an increase in the eﬀective
concentration within the cell, enhanced protein stability, and
additional regulatory ﬂexibility.11 While self-association is not
necessarily a prerequisite for activity, the active sites of perhaps
one-sixth of all oligomeric enzymes are located at highly
stabilized interfaces between two peptide chains.11
Such is the case with thiamin diphosphate (ThDP)-dependent
enzymes.12,13 While this group of enzymes has evolved to
catalyze a wide range of chemical reactions,14 X-ray structures
have shown that overwhelmingly they have developed only one
way to bind the ThDP cofactor, namely at the interface between
twomonomers. This creates two active sites per homodimer with
each monomer contributing either a pyrimidine binding (PYR)
domain or a diphosphate binding (PP) domain to a given active
site (Figure 1). At a minimum, therefore, any ThDP-dependent
enzyme must form a dimer.12,13 Curiously, until recently, all the
ThDP-dependent enzymes whose sole in vivo function is to
catalyze a decarboxylation reaction were found to be
homotetramers, albeit more accurately described as dimers of
active dimers.15−21 The branched-chain 2-keto acid decarbox-
ylase from Lactococcus lactis (KdcA, EC 4.1.1.72) was the ﬁrst to
deviate from this trend when its X-ray structure [Protein Data
Bank (PDB) entry 2VBG] showed to it be dimeric.22
Intriguingly, although the archetypal ThDP-dependent decar-
boxylase, pyruvate decarboxylase from Saccharomyces cerevisiae
(ScPDC, EC 4.1.1.1), is a tetramer in the crystal lattice, analytical
ultracentrifugation (AUC) experiments showed it to be a dimer
at low solution concentrations.23 Further, using urea as a
denaturant, it was possible to shift the dimer−tetramer
equilibrium in favor of the dimer and to demonstrate that the
dimer was catalytically active.24,25
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Benzoylformate decarboxylase (BFDC, EC 4.1.1.7) is another
ThDP-dependent decarboxylase that has been shown to be a
homotetramer.18 First identiﬁed as part of the mandelate
pathway of Pseudomonas putida,26 BFDC catalyzes the non-
oxidative decarboxylation of benzoylformate to yield benzalde-
hyde and carbon dioxide.27 Not surprisingly, given the similarity
of their reactions, there is considerable structural homology
between BFDC and PDC, including the conservation of several
catalytic residues. As part of a project examining the evolution of
ThDP-dependent enzymes, we have been attempting to
interconvert the two enzymes, but with limited success.28,29
Unlike ScPDC, it has never been determined whether BFDC is
active as a dimer, nor has it been shown what advantage, if any,
the tetramer provides to BFDC. Here, we report the use of site-
directed mutagenesis coupled with analytical centrifugation and
X-ray crystallography to answer two questions. (i) Can BFDC be
converted into a dimer? (ii) Is the tetramer required for
enzymatic activity?
■ MATERIALS AND METHODS
Primers were synthesized by Integrated DNA Technologies.
Recombinant alcohol dehydrogenase from Equus caballus
(HLADH) was obtained as described previously.30 Reduced β-
nicotinamide adenine dinucleotide (NADH), isopropyl β-D-
thiogalactopyranoside (IPTG), and benzoylformate were
purchased from Sigma-Aldrich. A gel ﬁltration calibration kit
(high molecular mass) and HiPrep 16/60 Sephacryl S-200 High
Resolution column were purchased from GEHealthcare. Nickel-
nitrilotriacetic acid (NTA) resin was purchased fromQiagen. Pfu
DNA polymerase was purchased from Stratagene. Buﬀers and
other assay reagents were purchased from either Sigma-Aldrich
or Fisher Scientiﬁc and were of the highest grade commercially
available. Sequencing was conducted by the University of
Michigan DNA Sequencing Core Facility.
Analysis of Dimer and Tetramer Interfaces. The X-ray
structure of wt BFDC at 1.60 Å resolution (PDB entry 1BFD)
was used as the model for analysis of the interfaces. The
SPPIDER server (http://sppider.cchmc.org) was used to
calculate the total surface area and the interface surface area
and to verify that residues selected for mutagenesis were not
involved in the formation of the active dimer. The PDB
visualization program PyMOL (Schrödinger, LLC) was used to
identify targets for mutagenesis and for the preparation of ﬁgures.
Plasmids. Mutagenesis was performed on BFDC expression
vector pET24dBFDC-His.31,32 Primers (Table 1 of the
Supporting Information) were designed, and site-directed
mutagenesis was performed according to the QuikChange
mutagenesis protocol (Agilent) utilizing Pfu DNA polymerase.
DpnI was used to digest parental DNA prior to its transformation
into chemically competent TOP10 cells. Each plasmid used for
protein expression had the complete mdlC gene sequenced to
ensure that only the desired mutations were present.
Protein Expression and Puriﬁcation. Expression of wt
BFDC and its variants was conducted in Escherichia coli strain
BL21(DE3). Induction of the recombinant protein was initiated
with 1 mM IPTG. Following induction, the cultures were grown
at room temperature overnight (18−20 h). Enzymes were
puriﬁed as described previously.31 The protein was exchanged
into BFDC storage buﬀer [100 mM KHPO4, 1 mMMgSO4, 0.5
mM ThDP (pH 6.0), and 10% (v/v) glycerol] and concentrated
using Amicon Ultra centrifugal ﬁlters (Millipore). Purity was
assessed by sodium dodecyl sulfate−polyacrylamide gel electro-
phoresis, and the protein concentration was determined from the
absorbance at 280 nm using a molar extinction coeﬃcient of
62220, calculated from the sequence of wt BFDC with the
ExPASy ProtParam tool.33 Enzymes were stored at −80 °C until
they were required.
Steady-State Kinetic Analysis ofWild-Type and Variant
BFDC. The coupled activity assay of the puriﬁed enzymes was
performed as described previously.34 The assay mixture
contained bovine serum albumin (BSA, 1 mg/mL), NADH,
and HLADH in 100 mM potassium phosphate buﬀer (pH 6.0),
and varying concentrations of benzoylformate in a ﬁnal volume
of 1mL. Reactions were conducted at 30 °C and were initiated by
the addition of the enzyme. Assays were performed in triplicate.
Steady-state kinetic parameters were determined by ﬁtting the
initial rate data to the Michaelis−Menten equation, using the
enzyme kinetics module of SigmaPlot version 9.0.1 (Systat
Software, Inc.).
For the equilibrium denaturation studies, assays were
conducted in denaturation buﬀer using the direct UV assay of
Hegeman.26 The decrease in benzoylformate concentration was
monitored at 334 nm.
Molecular Mass Predicted by Size-Exclusion Chroma-
tography (SEC). Size-exclusion chromatography (SEC) was
performed using an AKTA fast performance liquid chromatog-
raphy system (GE Healthcare) equipped with a HiPrep 16/60
Sephacryl S-200 High Resolution column (1.6 cm× 94 cm). The
column was equilibrated with running buﬀer [50 mM NaPO4
and 150 mM NaCl (pH 7.5)] prior to calibration. Blue Dextran
was used to determine the void volume of the column. A standard
curve was obtained using a high-molecular mass gel ﬁltration
calibration kit (GE Healthcare). Protein standards were loaded
according to the manufacturer’s protocol. BFDC variants were
loaded onto the column via injection into a 2 mL loop at
concentrations ranging from 0.1 to 1 mg/mL in a total volume of
400 μL. Kav values were calculated and used to predict the
molecular mass and oligomerization state of the BFDC variants
SEC-MALS Analysis. Size-exclusion chromatography multi-
angle light scattering (SEC-MALS) was performed on wt BFDC
and the R141E/A306F and R141E/Y288A/A306F variants.
Three concentrations, 3.1, 1.5, and 0.75 mg/mL, were used for
themutant BFDC proteins. For thewt enzyme, concentrations of
2.0, 1.0, and 0.75 mg/mL were used. A Superdex 200 column
coupled to the three-angle miniDawn TREOS and Optilab-Trex
instrument (Wyatt Technologies) was used for collection of the
light scattering and refractive index data. The system is coupled
to an Agilent 1100 high-performance liquid chromatography
Figure 1. ThDP (yellow) in the active site of BFDC. The cofactor
interacts with both the phosphate-binding domain of monomer A
(green) and the pyrimidine-binding domain of monomer B (orange).
Prepared using PyMOL using data from PDB entry 1BFD.
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system at a ﬂow rate of 0.45 mL/min with an in-line
spectrophotometer. Astra (version 6.0.3) was used to analyze
the collected data.
Analytical Ultracentrifugation. Sedimentation velocity
experiments were conducted on Beckman-Coulter XLA and
XLI analytical ultracentrifuges. wt BFDC and the R141E/A306F
and R141E/Y288A/A306F variants were dialyzed extensively
against a buﬀer containing 100 mM NaPO4 (pH 7.5), 300 mM
NaCl, 1 mM MgCl2, and 35 μM ThDP. The sample
concentrations ranged from 0.25 to 1.0 mg/mL. The samples
were then centrifuged at 42000 rpm using two-sector 1.2 cm
path-length carbon-ﬁlled Epon centerpieces. The experiments
were conducted on an An-50 Ti rotor at 20 °C. The density and
relative viscosity of the buﬀers were calculated with SEDNTERP
version 1.09 (http://www.jphilo.mailway.com/download.
htm#SEDNTERP) to be 1.01949 g mL−1 and 0.01069 P,
respectively. On the basis of its sequence, the partial speciﬁc
volume (vbar) of the protein was calculated with SEDNTERP to
be 0.7340 mL g−1. The samples were monitored at 280 nmwith a
4 min delay and 150 scans. The c(s) distributions were analyzed
using SEDFIT version 14.3e.35 Molecular masses were calculated
from the c(s) data using a shape assumption.
Urea Unfolding Monitored by Circular Dichroism (CD)
Spectroscopy and Fluorescence Spectrophotometry. wt
BFDC and the R141E/A306F variant (0.15 mg/mL) were
incubated overnight at 4 °C with varying urea concentrations in
50 mM phosphate buﬀer (pH 6.0). Far-UV CD experiments
were conducted on a Jasco J-810 spectropolarimeter. Unfolding
was monitored by changes in ellipticity at 222 nm in a cell with a
path length of 0.1 cm at 20 °C. Spectra were averaged over ﬁve
scans, and the scan speed was set at 20 nm/min with a response
time of 1 s and a slit width of 1 nm.
Fluorescence emission spectra were recorded on a Varian Cary
Eclipse ﬂuorescence spectrophotometer. The intrinsic ﬂuores-
cence of wt BFDC and the R141E/A306F variant, both at 0.15
mg/mL in varying concentrations of urea in 50 mM phosphate
buﬀer (pH 6.0) at 20 °C, was recorded from 295 to 450 nm using
an excitation wavelength of 280 nm. The bandpass for excitation
and emission was set at 5 nmwith a scanning rate of 200 nm/min.
Crystallization of the R141E and A306F Variants.
Crystals of BFDC R141E and BFDC A306F variants were
grown by the hanging drop diﬀusion method under the same
conditions used for the crystallization of wt BFDC.18 Storage
buﬀer was exchanged for crystallization buﬀer [0.1 mM MgCl2,
0.2 mM ThDP, and 25 mM NaHEPES (pH 7.0)]. The well
solution consisted of 0.1 M Tris (pH 8.5), 0.15 M CaCl2, and
22% PEG400 (v/v). Equal volumes of protein (10 mg/mL) and
well solution were pipetted onto a silanized glass slide and mixed.
A heavy precipitate immediately formed from this mixture, and
single crystals emerged from the precipitate within days. Crystals
were transferred to fresh crystallization buﬀer containing 36%
(v/v) glycerol as a cryoprotectant and mounted on Hampton
CryoLoops immediately prior to being ﬂash-frozen in liquid
nitrogen.
X-ray Data Collection.Diﬀraction data were obtained at 100
K on the 23-ID-D and 23-ID-B beamlines administered by GM/
CA-CAT at the Advanced Photon Source at Argonne National
Laboratory (Argonne, IL). Data sets for the R141E and A306F
variants were scaled to the I222 space group. Data reduction and
processing of data sets were achieved using the HKL2000
software package and the CCP4 suite of programs.36 Molecular
replacement was performed using the search model wt BFDC
(PDB entry 1BFD) with metals and waters removed. The
asymmetric unit for each variant contained a single monomer.
Structure Solutions and Reﬁnements. PHENIX was used
for model reﬁnement.37 After each round of reﬁnement, the
electron density was manually inspected and models were built
using Coot.38 Reﬁnement continued until Rfree and the
crystallographic R factor could no longer be improved. The
validity of the model was checked using the MolProbity server.39
All images were generated using PyMOL (Schrödinger, LLC).
■ RESULTS
Comparison of the Quaternary Structures of KdcA,
ScPDC, and BFDC. It is clear from their respective X-ray
structures that KdcA22 is a homodimer and that BFDC18 is a
homotetramer (Figure 2). Although ScPDC was initially
reported to be a homotetramer,40 structural analysis suggests
that its tetrameric form may arise simply by crystal packing.40 To
examine this possibility, we turned to the Solvent accessibility-
based Protein-Protein Interface iDEntiﬁcation and Recognition
(SPPIDER) server that can be used to predict the total surface
area of interfaces from a PDB ﬁle.41 Analyses were conducted on
three ThDP-dependent decarboxylases, KdcA (PDB entry
2VBF), ScPDC (PDB entry 1PYD), and BFDC (PDB entry
1BFD). In each case, the interface forming the active site, deﬁned
as the A−B interface (Figure 2), was clearly identiﬁed (Table 1).
There was no evidence of any dimer−dimer interface in the
KdcA structure, supporting the crystallographic ﬁnding of a
homodimer. Interestingly, no evidence was found for any
dimer−dimer interface when the ScPDC structure was used as
the search model. This reinforces the suggestion that the
tetramer observed in the crystal lattice of ScPDC might be an
artifact of protein crowding at higher enzyme concentrations.
Conversely, analysis of the X-ray structure of BFDC with
SPPIDER indicates a robust dimer−dimer interface accounting
for almost 10% of the total surface are of the enzyme (Table 1).
Analysis of the Dimer−Dimer Interfaces of BFDC.
SPPIDER analysis of the quaternary structure of BFDC shows
Figure 2. Deﬁning the interfaces of BFDC monomers. (A) BFDC
tetramer. Monomer A is colored green, monomer B orange, monomer C
cyan, and monomer D magenta. (B) Cartoon with lines indicating
interactions between the monomers (circles) and ThDP (diamonds).
The active sites (one per monomer) are found at the A−B interface.
(C−E) A−B, A−C, and A−D interfaces, respectively. Figures based on
data from PDB entry 1BFD.
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that each chain has signiﬁcant interactions with every other chain
in the tetramer (Table 1). The interface that forms the active
dimer, the A−B interface, was calculated to have the largest total
area of contact (3540 Å2),∼17% of the solvent accessible surface
area of the monomer. It seems logical that disruption of the A−B
interface would result in a loss of enzyme activity; therefore, our
attempts to convert BFDC into a dimer were focused on
disrupting the A−C and A−D interfaces (Figure 2).
The A/D interface was the next largest, with a total surface area
of ∼1600 Å2 or about 8% of the total monomer A surface area.
Here Tyr288 and Ala306 were identiﬁed as possible candidates
for mutagenesis. Tyr288 of monomer A has 12 points of contact
within 5 Å of monomer D (Figure 3), and it was reasoned that
elimination of most of these interactions by removal of the
phenyl ring should result in a less stable A/D interface.
Additionally, the methyl side chain of Ala306 on monomer A
is located in a shallow hydrophobic cleft of monomer D (Figure
3), and it was thought that replacement by a bulkier residue such
as phenylalanine would not be tolerated, and may help disrupt
the interface.
At∼500 Å2, the A−C interface accounts for∼2.5% of the total
surface area of monomer A and is mostly comprised of residues in
charge−charge interactions. The side chains of Glu107 and
Asp114 of monomer A, for example, form salt bridges with
Arg141 and Arg120, respectively, of monomer C (Figure 4).
Because of the 2-fold symmetry, Arg120 and Arg141 of
monomer A also interact with Asp114 and Glu107 of monomer
C. These four positions were selected as targets for mutagenesis,
speciﬁcally to introduce like-charge repulsions in an attempt to
destabilize the dimer−dimer interface. A summary of the various
interactions, and the rationale for the mutagenesis experiments
can be found in Table S2 of the Supporting Information.
Kinetic and SEC Analysis of A−C and A−D Single-
Mutation Variants. All variants expressed as soluble protein.
Using the typical assay conditions described in Materials and
Methods, Km and kcat values of the A−D variants were very
similar to those of wt BFDC (Table 2). The A−C variants also
exhibited no change in their Km values, but compared to that of
wt BFDC, there was a modest 2−4-fold decrease in their kcat
values. All variants eluted from the SEC column at a volume
indicative of a tetramer (Table 2). On the basis of these results, it
appeared that the single mutations did not noticeably alter the
dimer−tetramer equilibrium or greatly aﬀect the overall catalytic
activity of the enzyme.
Generation and Analysis of the R141E/Y288A/A306F
Variant. The inability of a single mutation to produce a dimeric
BFDC prompted a reanalysis of the A−D and A−C interfaces.
The A−D interface accounts for nearly 10% of the total surface
area; therefore, it was not surprising that more than one
unfavorable interaction would be required to disrupt it. It was
noted that the hydrophobic pocket that accommodates Ala306
comprised Met145, Met148, and the hydrophobic region of the
Arg141 side chain. It was reasoned that replacement of Arg141
with a glutamic acid would have a dual eﬀect in that it would set
up an unfavorable interaction with Glu107 and reduce the
hydrophobicity of the Ala306 binding pocket. To maximize the
destabilizing interactions, the R141E/Y288A/A306F variant was
constructed. The triple mutant expressed well and was puriﬁed as
a soluble protein. When subjected to SEC chromatography at 1
mg/mL, it eluted at a volume similar to that of wt BFDC but, at
≤0.5 mg/mL, it eluted at a larger volume, suggestive of a change
in oligomerization state (Table 2). Unfortunately, it also was
inactive in the assay.
Veriﬁcation of the Quaternary Structure of wt BFDC
and the R141E/Y288A/A306F Variant. To validate the SEC
observations and to conﬁrm that the oligomerization state of the
triple mutant was indeed concentration-dependent, we turned to
a combination of analytical ultracentrifugation and SEC-MALS.
Sedimentation velocity experiments were performed, and the
sedimentation coeﬃcients (S) for wt BFDC were determined at
concentrations of 0.25, 0.5, and 1.0 mg/mL (Figure S1 of the
Supporting Information). At each concentration, an S value of
8.4 was calculated from a c(s) distribution (Table S3 of the
Supporting Information). The calculated molecular mass from
these experiments was 241 ± 22 kDa, which agrees with the
theoretical molecular mass of ∼229 kDa for the BFDC tetramer.
Additional SEC-MALS analysis provided a molecular mass of
235.1 ± 16.5 kDa, also corresponding to a tetrameric species
(Table S4 of the Supporting Information). Similar experiments
Table 1. SPPIDER Analysis of Monomer−Monomer
Interfacesa
interface
KdcA
surface
area
(Å2)
ScPDC
surface
area
(Å2)
BFDC surface
area (Å2)
ZmPDC
surface area
(Å2)
monomer 21856 21819 20611 22364
chain A−chain B 3458
(16%)
2819
(13%)
3475 (17%) 4204 (19%)
chain A−chain C ndb ndb 488 (2%) 611 (3%)
chain A−chain D ndb ndb 1601 (8%) 1226 (5%)
aSurface areas were calculated from PDB entries 2VBF (KdcA), 1PYD
(ScPDC), 1BFD (BFDC), and 1ZPD (ZmPDC) using the SPPIDER
server. bNo interface can be detected by SPPIDER.
Figure 3. Interactions at the A−D interface. (A) Tyr288 of monomer A
is found to have 12 points of contact (≤5 Å) with monomer D. (B)
Ala306 of monomer A is located in a shallow hydrophobic cleft of
monomer D.
Figure 4. Interactions at the A−C interface. View of charged residues
highlighting those with interatomic distances of ∼3 Å.
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were performed on the triple mutant, and by contrast, the S value
determined at the same concentrations was found to be 7.9
(Figure S1 of the Supporting Information). The SEC-MALS
analysis for the R141E/Y288A/A306F variant showed a
pronounced concentration-dependent shift in both molecular
mass and retention time (Figure S2 and Table S4 of the
Supporting Information). All these changes pointed to a shift in
the dimer−tetramer equilibrium.
Analysis of the R141E/Y288A/A306F Permutation
Variants. Having seemingly changed the dimer−tetramer
equilibrium, we thought it was important to determine which
combination of mutations was crucial in bringing about the
change. Accordingly, the three permutations of the R141E/
Y288A/A306F mutant were constructed. Once again, the
variants were expressed as soluble proteins and could be assayed
under standard conditions. Like the single mutants, R141E/
Y288A, R141E/A306F, and Y288A/A306F variants all had Km
values similar to that of wt BFDC. Conversely, they all showed
considerable decreases in kcat values, with the greatest decrease
(∼3500-fold) seen for Y288A/A306F (Table 2). Each of the
variants was subjected to SEC chromatography at concentrations
ranging from 0.1 to 1mg/mL.While R141E/Y288A and Y288A/
A306F eluted at volumes indicative of a tetramer regardless of
concentration, the R141E/A306F variant exhibited concen-
tration-dependent changes similar to those shown previously by
the R141E/Y288A/A306F variant. In some ways, this was a
surprising result as the kcat value for R141E/A306F was 0.8 s
−1,
admittedly a ∼450-fold decrease over that of wt BFDC but still
much higher than that of the Y288A/A306F variant that
remained a tetramer. The Y288A and A306F single variants
retained nearly wild-type activity (Table 2), so it is not
unreasonable to assume that the double mutant exhibiting the
greatest decrease in activity would be the one most likely to show
alterations in its oligomerization state. Clearly, that is not the case
here, and the reasons for the reduced activity in this variant will
become the focus of a future investigation.
To explore this further, the R141E/A306F variant was
analyzed, in turn, by analytical centrifugation (Figure S1 of the
Supporting Information) and SEC-MALS (Figure S2 of the
Supporting Information). The calculated S value for the double
mutant was 7.3, signiﬁcantly lower than that of wt BFDC. This
number was obtained at all protein concentrations (Table S3 of
the Supporting Information). It was also apparent from the SEC-
MALS data that the R141E/A306F variant showed concen-
tration-dependent changes in retention time, which are reﬂected
in its molecular mass (Table S4 of the Supporting Information).
Figure 5 provides a ready comparison of the AUC and SEC-
MALS data for wt BFDC and the two variants, R141E/A306F
and R141E/Y288A/A306F. The continuous size distribution
analysis data, obtained at a protein concentration of 0.5 mg/mL
(8.6 μM), highlight the trend toward lower S values, indicative of
a smaller species. In addition, at 0.75 mg/mL, both variants have
a clear increase in retention time over that of wt BFDC (Figure
5B), conﬁrming a movement toward dimer formation.
Equilibrium Denaturation Measurements. The urea-
mediated unfolding of wt BFDC and the R141E/A306F variant
was followed by both intrinsic ﬂuorescence and CD spectros-
copy. To highlight any diﬀerences, the unfolding experiments
were conducted at an enzyme concentration of 0.15 mg/mL. At
this concentration, the wt enzyme is tetrameric whereas the
R141E/A306F variant is expected to be primarily dimeric. As
shown in Figure 6A, when monitored using the intrinsic
ﬂuorescence signal at 327 nm, the unfolding of wt BFDC
appears to have three transitions. Initially, between 0 and 0.5 M
urea, there is a small increase in ﬂuorescence. Another small
transition is observed on going from 0.5 to 2 M urea, while the
largest transition takes place between 2 and 6M urea. Potentially,
the ﬁrst corresponds to the dissociation of tetramers to dimers;
the second is that of the dimers to monomers, and the third
results from the unfolding of the monomers. Such a pattern was
also observed for ScPDC.25 By contrast, the unfolding of the
R141E/A306F variant showed only two transitions (Figure 6A),
most likely due to the initial unfolding of the dimer followed by
unfolding of the monomer.
Similar results were observed for wt BFDC when unfolding
was monitored by far UV-CD (Figure 6B). Further, the urea-
induced inactivation of wt BFDC is complete by 3.5 M urea
(Figure 6B), and it is evident that some degree of inactivation of
the wt enzyme has occurred even at urea concentrations as low as
0.25 M. This decrease in the activity of wt BFDC is presumably
caused by the dissociation of the tetramer. This result is in stark
contrast to that found in the same experiment conducted with
ScPDC. In that case, the enzyme was fully active at 1 M urea, and
dimers and tetramers were equally active.25 The unfolding of the
Table 2. Steady-State Kinetic Parametersa,b and Oligomerization Statesc of the BFDC Variants
variant kcat (s
−1)b Km (mM) kcat/Km (mM
−1 s−1)b oligomerization state at ≤0.5 mg/mL
wt BFDC 350 ± 30 (1) 0.30 ± 0.03 1200 (1) tetramer
Y288A 310 ± 20 (1) 0.25 ± 0.03 1200 (1) tetramer
A306F 250 ± 23 (1) 0.31 ± 0.09 890 (1.3) tetramer
R141E 180 ± 22 (2) 0.19 ± 0.05 950 (1.3) tetramer
R120E 130 ± 26 (3) 0.29 ± 0.10 450 (2.7) tetramer
E107R 130 ± 10 (3) 0.33 ± 0.10 390 (3) tetramer
D114R 83 ± 12 (4) 0.25 ± 0.10 330 (3.6) tetramer
E107R/D114R 0.8 ± 0.04 (440) 0.35 ± 0.05 2 (585) tetramer
R141E/Y288A 15 ± 2 (23) 0.21 ± 0.03 70 (17) tetramer
R141E/A306F 0.8 ± 0.3 (440) 0.25 ± 0.02 3 (400) evidence of dissociation
Y288A/A306F 0.1 ± 0.01 (3500) 0.33 ± 0.03 0.3 (4000) tetramer
R141E/Y288A/A306F nadd nadd nadd evidence of dissociation
L109A 3.9 ± 0.3 (90) 0.80 ± 0.1 4.8 (250) nde
L110A 1.5 ± 0.3 (230) 2.8 ± 0.3 0.5 (2400) nde
aValues are means of three independent determinations ± the standard error (SE). All variants were prepared with C-terminal hexahistidine tags and
assayed as described in Materials and Methods. bIn parentheses are fold decreases over the wt value. cOligomerization states for variants were
determined by SEC as described in Materials and Methods. dNo activity detected. eNot determined.
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R141E/A306F variant, monitored by CD, followed a pattern
almost identical to that observed in the ﬂuorescence experiments
(Figure S3 of the Supporting Information). Unfortunately,
because of low levels of activity, it was not possible to follow the
inactivation of the R141E/A306F variant. Nonetheless, the
experiments did demonstrate clearly that there were distinct
diﬀerences in the urea-mediated denaturation of wt BFDC and
the R141E/A306F variant, providing additional evidence that the
equilibrium has shifted toward dimer formation in the latter.
X-ray Structures of the R141E and A306F Variants.
Attempts to crystallize the double and triple variants were
unsuccessful. However, the X-ray structures of the R141E (PDB
entry 4MPR) and A306F (PDB entry 4MQ5) variants were
determined to resolutions of 1.40 and 1.50 Å, respectively (Table
3). Both exhibited the same fold as the wt enzyme; their space
group and cell dimensions were also identical, and as previously
observed with other BFDC structures, residues 461−468 had the
highest B factors of any region of the protein.18,42 The active sites
were also unchanged, and given that the kinetic parameters for
these variants were similar to those of wt BFDC (Table 2), this
result was not entirely unexpected. However, the mutations did
bring about some unanticipated structural changes that are
worthy of comment.
It was predicted that mutating Arg141 to a glutamate would
result in a variant that not only would be unable to form a salt
bridge with Glu107 but also would create like-charge repulsion
between Glu107 and Glu141. Surprisingly, the crystal structure
of the R141E variant revealed the carboxylate group of Glu141 is
complexed to a Na+ ion, as well as the indole moiety of Trp125
(Figure 7). Four water molecules were also coordinated to the
sodium ion, as was the carbonyl of Gly105. One of these waters
was located within 3 Å of the carboxylate of Glu107. It seems that
these unexpected interactions were suﬃcient to alleviate the
predicted charge−charge repulsion that was expected to tilt the
equilibrium toward the dimeric state.
Perhaps the most surprising observation was that the A306F
substitution resulted in the displacement of the side chain of
Arg141. This meant that the guanidinium group of arginine
forms an intramonomer salt bridge with the side chain of Glu134
rather than the intermonomer interaction with Glu107 (Figure
8). The net result was that the additional bulk of the new
phenylalanine residue was readily accommodated.
■ DISCUSSION
In his structure-based analysis of the domain relationships
inherent to the ThDP-dependent enzymes, Duggleby12
proposed that the original enzyme was a protein that contained
binding sites for both ends of the ThDP molecule. Dimerization
provided an advance by which the intrinsic activity of the cofactor
was enhanced. Duplication of the gene for the primitive
Figure 5. (A) Distribution of normalized c(s) values for wt BFDC and
the R141E/A306F and R141E/Y288A/A306F variants. In each case, the
protein concentration was 0.5 mg/mL (8.6 μM). At that concentration,
the S values are 8.4, 7.9, and 7.3 for the wt, triple mutant, and double
mutant, respectively. (B) SEC-MALS analysis of wt BFDC and the two
variants (0.75 mg/mL) shows the change in the dimer−tetramer
equilibrium for the latter.
Figure 6. Equilibrium unfolding of BFDC by urea. (A) Relative changes
in intrinsic ﬂuorescence at 327 nm (λex at 280 nm) forwtBFDC (●) and
the R141E/A306F variant (◇). (B) Relative changes in ellipticity at 222
nm (●) and enzymatic activity (○) for wt BFDC. All changes were
monitored at 20 °C. The results shown are the average of at least two
independent measurements.
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decarboxylase resulted in an α2β2 heterotetramer, likely a still
more eﬃcient enzyme. Subsequently, gene fusion led to the
combination of the PP and PYR domains, giving rise to,
eﬀectively, an (αβ)2 protein that can be seen to this day in
phosphonopyruvate decarboxylase.12,43 The more modern
ThDP-dependent decarboxylases at some point acquired a
third domain, the TH3 domain, which fused between the PYR
and PP domains.12 A broadly similar evolutionary pattern has
also been postulated on the basis of sequence analysis, with the
added suggestion that recruitment of the TH3 domain was
accompanied by tetramer formation.13
What was not considered in any of these discussions is whether
tetramer formation is essential or, if not, what advantage accrues
due to tetramer formation. Allosteric regulation may have been a
possible candidate, particularly as KdcA is a dimer and exhibits
Michaelis−Menten kinetics whereas ScPDC is subject to
allosteric activation by its substrate.44 However, this explanation
is made less likely by the X-ray structures of ScPDC in its
unliganded45 and substrate-activated forms,46 which both show
the enzyme to be tetrameric. Further, studies by Killenberg-Jabs
et al.24,25 have found that ScPDC exists as an equilibrium mixture
of dimers and tetramers under physiological conditions, and that
there was no diﬀerence in the steady-state activity between the
two states. Altogether, it would appear that the ability to form a
tetramer is not a prerequisite for allosteric activation.
In contrast to ScPDC, BFDC is tetrameric and obeys
Michaelis−Menten kinetics. In many ways, it is more comparable
to the PDC from Zymomonas mobiliz (ZmPDC), which has
similar properties.17 The similarity was conﬁrmed by SPPIDER
analysis, which showed that an individual monomer in both
BFDC and ZmPDC makes signiﬁcant contact with the other
three monomers in the tetramer (Table 1). This is quite diﬀerent
from the cases of KdcA and ScPDC, which show contacts only
between the two monomers comprising the catalytic dimer.
Attempts to alter the dimer−tetramer equilibrium of BFDC by
disrupting the noncatalytic monomer−monomer interfaces with
point mutations were unsuccessful. Initially, it took the
introduction of three mutations before any change was observed
by SEC. This shift in equilibrium was conﬁrmed by analytical
ultracentrifugation. The R141E/Y288A/A306F variant showed
no activity in the standard assay or in those containing 500 μg/
mL enzyme. Subsequently, it was shown that two mutations,
R141E and A306F, were suﬃcient to alter the dimer−tetramer
equilibrium. At an assay concentration of 40 μg/mL, this variant
showed a considerable (∼450-fold) reduction in its kcat from that
of wt BFDC, but it was impossible to say whether this was a
reﬂection of the presence of tetramer in solution or the dimer
indeed retained some activity. To investigate the latter
possibility, we turned to equilibrium denaturation experiments.
It has been shown that, in a 0.5 M urea solution, ScPDC forms
dimers, and those dimers have the same speciﬁc activity as the
tetramers.24 Here we found that BFDC has a urea unfolding
curve similar to that of ScPDC, regardless of whether unfolding
was measured by intrinsic ﬂuorescence or by CD. However,
unlike ScPDC, BFDC showed a rapid loss of activity, even at urea
concentrations as low as 0.25 M. Taken together, our data
suggest that, to be catalytically active, it is necessary for BFDC to
be a tetramer.
Table 3. Data, Model, and Crystallographic Statistics for the
Structures of R141E and A306F BFDC
R141E BFDCa A306F BFDCb
Data Collectionc
beamline APS, GM/CA-CAT,
23-ID-D
APS, GM/CA-CAT,
23-ID-B
wavelength (Å) 1.03 1.03
space group I222 I222
cell constants a = 80.98 Å a = 81.63 Å
b = 95.97 Å b = 95.54 Å
c = 137.3 Å c = 137.6 Å
α = β = γ = 90° α = β = γ = 90°
no. of unique
reﬂections
104731 85254
resolution limit (Å) 1.40 (1.40−1.45) 1.50 (1.50−1.53)
completeness (%) 99.8 (99.8) 99.4 (100)
redundancy 7.2 (7.1) 5.2 (5.0)
I/σI 27 (2.9) 46 (8.7)
Rmerge (%) 8.5 (78) 5.0 (24)
Reﬁnement
resolution range (Å) 1.40−48.0 1.50−26.4
Rfree test set size 1997 2000
Rcryst (%) 12.45 11.96
Rfree (%) 14.96 14.72
no. of atoms
total 4738 4730
protein 4116 4108
water 591 591
overall B factor 12.15 12.78
rmsd
bond lengths
(Å)
0.015 0.009
bond angles
(deg)
1.563 1.289
aPDB entry 4MPR. bPDB entry 4MQ5. cValue in parentheses are for
the highest-resolution shell.
Figure 7. Potential Glu141−Glu107 interaction avoided in the R141E
variant. Instead, Glu141 is found coordinated to Trp125 and an
additional Na+ ion. Blue dashes indicate distances of ≤3 Å.
Figure 8. A306F variant provided an unexpected rearrangement in the
A−D interface. (A) wt BFDC showing the original positions of Met145
and Arg141. (B) Phe306 causes Met145 and Arg141 to adopt new
rotamers, the latter stabilized by interaction with Glu134. Blue dashes
indicate a distance of ∼3 Å. Red dashes indicate distances of ≤4 Å.
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Although that may be a reasonable conclusion, it is still not
clear why the tetramer is necessary. Although all the single
variants were very active, indicating that they were still
tetrameric, the X-ray structures of both R141E and A306F
provided some clues, with the most insightful piece of
information coming from the crystal structure of the A306F
variant. It was predicted that replacing Ala306 with phenylalanine
would result in a steric clash that would help destabilize the
tetramer. Surprisingly, the A306F structure revealed a rearrange-
ment of the shallow pocket, by which the additional steric bulk of
the phenylalanine was accommodated (Figure 8). This was due
to the displacement of the side chain of Arg141 and Met145,
which resulted in a larger binding pocket. The new rotamer of
Arg141 saw the loss of the intermonomer interaction with
Glu107 and the formation of a new intramonomer bond with
Glu134 (Figure 8). Extrapolating to the R141E/A306F variant,
we could assume that rather than Glu141 forming a salt bridge
with Glu134, the interaction would be unfavorable. Potentially,
this could cause Glu141 to spring back into its “original” position,
making the accommodation of Phe306 more diﬃcult. In the
R141E structure, the enzyme used an additional sodium ion to
help adapt to the potential Glu107−Glu141 contact (Figure 7).
This may not be feasible in the R141E/A306F variant. The net
result would be that the A−C and A−D interfaces are both
destabilized, pushing the equilibrium toward the dimer as
suggested by the SEC and equilibrium denaturation experiments.
Again, this is speculation, and it does not provide any insight
into the apparent necessity for BFDC to be tetrameric to be
catalytically active. Still, it is possible to take the speculation a
little further by looking more closely at structural diﬀerences
among BFDC, KdcA, and PDC. The three all belong to the
decarboxylase-like (DC) structural clade of ThDP-dependent
enzymes.12 The vast majority of enzymes of the DC clade possess
an inner active site loop that contains residues known to be
critical to their catalytic mechanism. For example, the loops of
ScPDC, 3-indole-pyruvate decarboxylase, phenylpyruvate de-
carboxylase, and KdcA all include two adjoining histidine
residues sometimes termed the HH motif.47 Mutagenesis of
either histidine results in a decrease in catalytic activity of orders
of magnitude.48−50 Conversely, although the active site of BFDC
also contains two catalytically important histidine residues, these
are not located on the inner loop. Instead, the loop of BFDC
houses two contiguous leucine residues, Leu109 and Leu110.
Alignment of the sequences of enzymes annotated as BFDCs in
the thiamin enzyme engineering database (TEED) shows that
Leu110 is completely conserved, and that leucine, or another
hydrophobic residue, is invariably found at position 109.51
Examination of the X-ray structure of BFDC in complex with
benzoyl phosphonic acid methyl ester (MBP), an analogue of
benzoylformate, shows that Leu109 lines the phenyl-binding
pocket of BFDC and that Leu110 has ﬁve points of contact
within 5 Å of the glyoxylate analogue portion of MBP (Figure 9).
From this structure, it appears that Leu110 acts as a clamp to lock
the glyoxylate moiety into the perpendicular arrangement of the
carboxylate group to the thiazolium−C2α bond. This geometry
is thought to promote decarboxylation by allowing the maximal
overlap of the π electrons of the thiazolium ring and the p orbital
of the scissile bond.52,53 Intriguingly, the active site loop of BFDC
is bookended by Glu107 and Asp114, which, of course, interact
with Arg141 and Arg120, respectively, in the A−C interface
(Figure 4). It is not unreasonable to imagine that these two salt
bridges may be responsible for maintaining the correct
positioning of Leu109 and Leu110 within the active site of
BFDC, thereby contributing to both the overall hydrophobicity
of the active site and the correct position of the substrate within
it.
To assess the importance of the two leucine residues, both
Leu109 and Leu110 were replaced, in turn, with alanine. Both
variants showed decreases in kcat of 2 orders of magnitude, while
L110A also exhibited a 9-fold increase in Km (Table 2). Overall,
the changes were broadly in line with those observed with the
R141E/A306F variant. It would appear that the decrease in
activity observed with the latter may be due to movement in the
inner loop resulting in the misalignment of Leu109 and Leu110
within the active site. To test this assumption, the E107R/D114R
double variant was generated to completely disrupt the A−C
interface, simultaneously preventing the correct positioning of
both Leu109 and Leu110. While the individual substitutions
produced only a modest eﬀect on catalysis, the catalytic eﬃciency
of the E107R/D114R variant was∼600-fold lower than that ofwt
BFDC (Table 2). It is notable that the kcat and Km values for this
variant were very similar to those of R141E/A306F, yet SEC data
suggested that the E107R/D114R variant remained a tetramer.
On that basis, it may be that the integrity of the dimer interface,
rather than the tetrameric structure per se, is of paramount
importance.
■ CONCLUSION
We have demonstrated that, in some cases, only two point
mutations are required to alter the dimer−tetramer equilibrium
of BFDC. In addition, it is apparent that the shift in equilibrium
toward dimer formation is accompanied by a loss of catalytic
activity. Finally, we provide evidence that suggests the tetrameric
structure of BFDC has evolved as a means of positioning and
stabilizing the active site loop residues, Leu109 and Leu110.
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